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MISPLACED MANDATE:
AN EXAMINATION OF FDA'S SILICONE BREAST IMPLANT POLICY
Why did the Food and Drug Administration (FDA) suddenly call
for a forty-ve day moratorium on silicone gel breast implants in 1
992 and then ban virtually all cosmetic breast implants' only months
after an FDA advisory panel had recommended that silicone breast
implants remain on the market for both reconstructive and cosmetic
uses?2 Is FDA's policy, which remains in force today, justied? What
is FDA's mandate, and has FDA overstepped it in banning cosmetic
breast implants?
This paper explores these questions. First, it traces the use of
silicone breast implants in the United States; next, it examines the
process that led to FDA's precipitous policy reversal; and nally~
it concludes with an assessment of current FDA policy.
SILICONE BREAST IMPLANTS
Medical Use of Silicone
Silicones are a family of inorganic silicon oxide polymers with
elastomeric properties that have wide applicability in modern medicine.
Medical silicone (polydimethylsiloxane) can be formulated
1 FDA, U.S. Department of Health and Human Services, Pub.
No. P92-I (1 992) (H.H.S. News).
2 FDA, U.S. Department of Health and Human Services, Pub.
No. T91 -72 (1991)
(Talk Paper).
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in varying ways. Depending on the additives with which it is
combined, it can appear in liquid, gel, or solid form.3
Although developed in the 1 930s, medical silicone initially was
used clinically during World War II { as a lubricant for glass sy-
ringes to ensure reliable plunger functioning.4 It was rst employed
in plastic surgery to waterproof wound dressings.5 Today silicone is
extensively used in a wide range of medical devices: as a coating for
needles, catheters, and silk sutures; as antifoams for gastric bloating;
as tubing for gastrointestinal, intravenous, and intra-arterial admin-
istration of nutrients and drugs; as implants for ngers, wrists, el-
bows, and shoulders; as pacemaker covers; and as breast, penile, and
testicular implants{to name only a representative sample of uses.6
History of Silicone Breast Implants
Silicone breast implants are elasticized silicone rubber pouches
lled with silicone gel.7 Since 1962, when they rst came on the
market, silicone breast implants have been implanted in 3 Jack C.
Fisher, The Silicone Controversy|When Will Science Prevail?, 326 NEW
ENG. J. MED. 1696 (1992).
4 Id.
5 J.B. Brown et al., Silicones in Plastic Surgery: Laboratory and Clinical
Investigations, A Preliminary l?eport, 1 2 Plast. Reconstr. Surg. 374-376
(1 953).
6 Ten Randall, Medical News & Perspectives, 268 JAMA 1 2 (1992);
Council on Scientic Aairs, Silicone Gel Breast Implants, 21 JAMA
2602 (1993).
~ Of all silicone medical devices, only silicone breast, chin, hiatal
hernia, and testicular implants contain silicone gel. Id.
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between 1 and 2.2 million women in the United States and Canada
alone.8 According to FDA estimates, approximately 20 percent of all
breast implants have been for reconstructive purposes (as a follow-
up to a mastectomy) and 80 percent have been purely for cosmetic
reasons.9
A number of medical concerns have been raised by silicone gel
implants. These include silicone gel penetration or bleed (seepage of
microdroplets of silicone gel through the semipermeable membrane
of the silicone envelope); brous capsular contracture (painful hard-
ening of the breast); rupture of the silicone envelope; interference
with early tumor detection; and a variety of connective-tissue, au-
toimmune diseases such as scleroderma, rheumatoid arthritis, hu-
man adjuvant disease, and lupus.10
Since 1 981, approximately 1 0,000 lawsuits have been led against
the manufacturers of silicone breast implants.1 1 A number of large
individual claims have been awarded in recent years.12
8 Jorge Sanchez-Guerrero and Matthew H. Liang, Silicone Breast
Implants and
Connective Tissue Diseases: No Association Has Been Convincingly Estab-
lished,
309 BRITISH MEDICAL JOURNAL 822 (1994).
9 FDA, U.S. Department of Health and Human Services, Pub.
No. T9 1-18 (1991) (Talk Paper).
10 Rebecca Weisman, Reforms in Medical Device Regulation: An Ex-
amination of the Silicone Gel Breast Implant Debacle, 23 GOLDEN GATE
U.L. REV. 973.
11 Charlotte Allen, Jurisprudence of Breasts, 5 STAN. L. & POL'Y
REV. 83 (1994).
1 2 See, e.g., Hopkins v. Dow Corning Corp., CA 9, No. 92-161
32 (9th Cir.
1 994)(upholding a $7.3 million individual award, including $6.5 in
punitive
damages).
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There have also been a growing number of settlements, capped
in the fall of 1 994 by a nationwide class-action suit that was settled
for over $4 billion.13
FDA REGULATION OF SILICONE BREAST IMPLANTS
In 1 938, Congress passed the Federal Food, Drug, and Cosmetic
Act, which authorizes FDA to regulate food, drugs, and cosmet-
ics sold or transported in interstate commerce. In 1 976 Congress
passed the Medical Device Amendments, which substantially ex-
panded FDA's regulatory powers vis a vis medical devices in order
to assure their safety and eectiveness.
After the 1 976 Amendments, all medical devices (that is, those de-
vices marketed intentionally for medical purposes)'4 are subject to
the general regulatory controls of the 1938 Act, including the provi-
sions relating to adulteration, misbranding, andgood manufacturing
practices. In addition, the Amendments require FDA to classify all
medical devices into one of three regulatory categories based on the
need for proof of safety and eectiveness.
1 3 In Re Breast Implant Litigation, DC NAIa, MDL No. 926
(1994).
1 4 A device is any instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or related
article, including any component, part, or accessory, which is|( 1)
recognized in the ocial National Formulary, or the United States
Pharmacopeia, or any supplement to them, (2) intended for use in
the diagnosis of disease or other conditions, or in the cure, mitiga-
tion, treatment, or prevention of disease, in man or other animals,
or (3) intended to aect the structure or any function of the body of
man or other animals, and which does not achieve any of its principal
intended purposes through chemical action within or on the body
of man or other animals and which is not dependent upon being
metabolized for the achievement of its primary intended purposes.
21 U.S.C ~ 321 (h) (1994).
4
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Class I devices are those for which the general regulatory con-
trols of the 1 938 Act are sucient to assure safety and eective-
ness. Classes II and Ill include devices for which general controls
are not sucient to assure safety and eectiveness; Class II devices
are those for which sucient information exists to establish a per-
formance standard; Class Ill devices are those for which sucent
information to establish a performance standard does not as yet
exist. In addition, Class Ill includes all new devices introduced af-
ter enactment of the 1 976 Amendments that are not substantially
equivalent to a pre-enactment device. 1 5
Because silicone breast implants had been on the market prior to
the passage of the 1 976 Amendments, they were considered
grandfathered in. It was not until 1 988 that FDA classied them
as aClass Ill device.'6 On April 10, 1991, FDA published a regulation
requiring manufacturers of silicone breast implants to submit proof
that the implants are safe and eective.17 On November 15, 1991,
an FDA advisory panel recommended virtually unanimously that,
although there was insucient information to warrent approval, sil-
icone breast implants be kept on the market while additional safety
and eectiveness information was collected and that no distinction
be made between reconstructive and augmentation
'5 See Peter Barton Hutt and Richard A. Merrill, FOOD AND
DRUG LAW at 745
(2nded. 1991).
1 6 55 Fed. Reg. 20,568 (1990).
17 FDA, U.S. Department of Health and Human Services, Pub. No.
T9 1-1 8
(1991) (Talk Paper).
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implantations.18 After the multimillion dollar jury award in Hop-
kins
v. Dow Corning Corp. (award to mastectomy implant recipient), a
panel member wrote to FDA urging reconsideration of the panel's
November recommendation. On January 6, 1 992, David Kessler,
FDA's Commissioner, appeared on national television and declared
a forty-ve day moratorium on the distribution andusueof all breast
implants.19 This dramatic and highly publicized FDA policy rever-
sal set o a media frenzy. When a reconvened advisory panel met
in February to hold a new hearing, its nding seemed to be a fore-
gone conclusion.20 Although four of the ve scientists on the panel
voted against restricting implants solely to patients desiring recon-
structive surgery, by a ve-to-four vote the committee recommended
the prohibition of purely cosmetic breast implants indenitely. Of
the ve members voting to limit the availability of implants, only
one had any scientic background and that person was not an ex-
pert in autoimmune diseases.2' On April 16, 1 992, FDA adopted the
panel's recommendations, thereby eectively ending all cosmetic sil-
icone breast implants in the United States.22
1 8 Mark A. Heller, Breast Implants: A Crisis Waiting to Happen at 247
(1994);
FDA Talk Paper supra. fn. 1.
1 9 Heller at 248; FDA supra fn. 2.
20 Heller at 249.
21 Id.
22 FDA, U.S. Department of Health and Human Services, Pub. No.
P-92-1 1 (1992) (H.H.S. News).
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ANALYSIS
FDA's current ban on silicone breast implants for strictly cosmetic
purposes is troublesome in many key respects.
Fallacy of FDA's Reconstructive/Cosmetic Distinction
In making a regulatory distinction between reconstructive and
cosmetic breast implantation, FDA has created an articial and ar-
bitrary distinction that is not logically justiable. There is no basic
dierence between the two types of implantations. Whether per-
formed for reconstructive or for augmentation purposes, breast im-
plantation is a totally discretionary procedure performed purely for
psychological and social reasons. In that sense, it is always an elective
cosmetic procedure. Indeed, it's important to note that even when
done as a follow-up to a mastectomy, implantation is a totally sep-
arate surgical procedure, performed many months after the original
cancer surgery.
The one genuine dierence between reconstructive and augmenta-
tion implantation is the average age of the implant recipients. Be-
cause cancer tends to strike older women (typically, in their fties
and sixties), while women having augmentation surgery tend to be
in their twenties and thirties, implantation devices inserted for aug-
mentation purposes are likely to stay in the recipient's body for
many more years and presumably need to be more durable. In ad-
dition, younger women may be more physically and sexually active
than older women and hence their implants may be subjected to
more stress. Finally, the need to be able to detect
7
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incipient breast cancer is greater for younger women who have
never had breast cancer than for women who have already been di-
agnosed with it; thus, the diculties that the presence of implants
poses to the accurate reading of mammographies (because of tis-
sue compression and visual blockage) can create additional risks for
augmentation implant recipients.
There are a number of responses to these concerns. Considering
that the projected lifespan of the average woman today is nearly
eighty years, even women having implantations in their forties and
fties can anticipate the need for their implants to last thirty years
or more. Thus, both categories of implant recipients share the same
legitimate concerns about the durability of their implants. As for
the purported age-related dierences in physical activity, these are
even more speculative; but even assuming that older women may be
somewhat less active than younger women, most older women are
still physically and sexually active, and thus, here too they share
the same concerns of younger recipients. Finally, other methods of
cancer detection that do not involve X-rays such as ultrasonogra-
phy and MRI imaging can be used to supplement mammograms.
Thus, in reality, the distinctions between older and younger implant
recipients are really dierences of degree rather than of kind. (Ad-
ditionally, implant recipients in these two categories may overlap in
age. Some women develop breast cancer in their early thirties and
some women in their forties may wish to augment their breasts.)
8
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Trivializing of Cosmetic Concerns and Benets
FDA seems to be equating cosmetic with frivolous or unimpor-
tant. This is an inappropriate and inaccurate value judgment. Amer-
ican society places a high value on being as physically attractive as
possible. The literature of social psychology is lled with studies
that show that physically attractive people have clear social, eco-
nomic, and professional advantages in American society.23 There is
considerable evidence that people react more favorably toward indi-
viduals who are physically attractive; that they tend to overgeneral-
ize from appearances, assuming that those who are attractive on the
outside also have attractive personal characteristics; that physically
attractive people are seen as being more socially competent, more
intellectually competent, better adjusted, and more self-assertive
than those who are less attractive.24
Therefore, wanting a cosmetic procedure to improve one's ap-
pearance isn't silly or trivial. It's an entirely rational and sensible
motive{and one deserving of respect. We may deplore the pressures
that women feel to conform to a stereotyped standard of
23 See Sharon S. Brehm and Saul M. Kassin, SOCIAL PSY-
CHOLOGY at 211-21 5 (2nded. 1993).
24 E. Hateld and S. Sprecher, Mirror, Mirror... The Importance
of Looks in
Everyday Life (1986); K.K. Dion, et al., What Is Beautiful Is Good, 24
J. of PERS.
AND SOC. PSYCH. 285; A.H. Eagly et al., What Is Beautiful Is Good,
But...:A
Me ta-Analytic Review of Research on the Physical Attractiveness Stereotype,
90
PSYCH. BULLETIN, 1.
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beauty, while at the same time defending their right to make their
own decisions.25
Inappropriate Moral and Social Value Judgments
FDA is statutorily mandated to base its decisions concerning
medical devices only on safety and eectiveness considerations. Nonethe-
less, in disallowing strictly cosmetic breast implantations, FDA seems
to be basing its decision on a moral judgment that cosmetic breast
implantation is improper and socially unworthy. As FDA Commi-
sioner David Kessler notes in defending FDA's distinction between
reconstructive and augmentation implantation, Certainly, as a so-
ciety, we are far from according cosmetic interventions the same
importance as a matter of public health that we accord to cancer
treatments. ... It makes little sense for the FDA to consider breast
augmentation of equivalent importance with an accepted compo-
nent of cancer therapy.26 Signicantly, FDA's decision to prohibit
cosmetic implants seems to be only minimally based on a belief that
cosmetic implants entail higher risks than reconstructive implants
(which might be more defensible).27 Rather
25 Marcia Angell, Breast Implants|Protection or Paternalism? 326
NEW ENG. J. MED. 1695,1696(1992).
26 David A. Kessler, The Basis of the FDA 's Decision on Breast Im-
plants, 326 NEWENG.J. MED. 1713,1715(1992).
27 Kessler does oer the rationale that the complications created by implants
in the use of mammography for detection of breast cancer raise the risks to
cosmetic implant recipients, but it seems more to be an eort to show
that FDA is not basing its decision on any moral judgments, coming as it
does after the following sentences: These restrictions on the use of silicone-gel
implants for breast augmentation are not based on any judgment about values.
Rather,
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(and somewhat astoundingly), Kessler claims that FDA's deci-
sion is based on FDA's determination that the needs of reconstruc-
tive and cosmetic implant recipients dier. As Kessler states: Some
argue, however, that it is inconsistent for the FDA to allow the use
of a medical device in some situations and not in others. In their
view, healthy women who have poor body images because they have
small or asymmetrical breasts have as greast a need for the device
as women who have breast cancer. This contention has a supercial
appeal. Although one can legitimately argue for a continuum of
need, in the end the needs of the patient who desires reconstructive
surgery dier from those of the patient who desires augmentation.28
Since this assessment is unrelated to the safety and eectiveness
concerns upon which FDA is supposed to base its actions, a strong
argument can be made that FDA's prohibition of cosmetic breast
implants while allowing reconstructive ones is an abuse of FDA's
enormous discretionary power. This kind of policy decision relating
to how society wishes to use its resources is best left to Congress.
It is simply not FDA's business to be making these kinds of broad
social policy decisions.
It is also not FDA's business to be making private value judgments
that are best left to the individual patient. The key to any risk/benet
analysis of a procedure of this sort{whose
the FDA has concluded that women who desire breast augmen-
tation are at higher risk than patients with breast cancer who have had a
mastectomy. Id. 28 Id.
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benets are purely psychological and social{is to determine the
value that this particular patient places on these benets. And
only the individual patient can make this determination. Some
mastectomy patients may be completely uninterested in reconstruc-
tive implants, while some women may be desparate for augmenta-
tion surgery. In such circumstances, the benets would be heavily
weighted in favor of the augmentation implant recipient. FDA is
simply not equipped to make this kind of benet analysis{and it
shouldn't be trying to do so.
Worth noting are the results of surveys of women with breast
implants, which report a greater than 90 percent incidence of satis-
faction with the procedure and the outcome.29
Finally, one must also ask whether FDA's precipitous policy rever-
sal did not in itself contribute to diminishing the potential benets
of this procedure. By creating an atmosphere of panic and unwar-
rented fears out of proportion to what is known about the risks,
it may have led some asymptomatic women with implants to opt
for surgical removal of their implants because of an alarm induced
by FDA and the media; and at the very least, FDA's actions have
signicantly impaired the peace of mind and quality of life of the
million or so women with implants.
29 J.C. Fisher and G.S. Brody, Breast Implants Under Siege: An His-
torical
Commentary, 1 J. LONG TERM EFF. MED. IMPLANTS 243;
Silicone Implant
Research Committee of the Plastic Surgery Educational Foundation,
Comments
From Plastic Surgery in Response to the FDA Proposed Rule and Request
for
Premarket Approval of Silicone Gel-Filled Breast Implants (1990).
12
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Paternlism
FDA's ban on cosmetic implants is paternalistic and profoundly
disrespectful of the intelligence and judgment of patients in general
and women in particular. In eect, FDA is saying that no matter
how well-informed a patient may be, no matter how strongly and
rationally motivated, and no matter how sound her doctor's advice,
the patient simply can't be trusted to make a rational choice. The
fact that the patients in question are all women only compounds
this paternalism.
This disparaging attitude toward the patient's ability to make an
informed choice permeates Commissioner's Kessler's comments:
It has become fashionable in some quarters to argue that women
ought to be able to make such decisions on their own. If members
of our society were empowered to make their own decisions about
the entire range of products for which the FDA has responsibil-
ity, however, then the whole rationale for the agency would cease
to exist.... To argue that people ought to be able to choose their
own risks, that government should not intervene, even in the face
of inadequate information, is to impose an unrealistic burden on
people when they are most vulnerable to manufacturers' assertions:
when they are desparately ill, when they are hoping against hope
for a cure, or when they are seeking to enhance their physical ap-
pearance. These are precisely the situations in which the legal and
ethical justication for the FDA's existence is greatest, however.30
This rather grandiose view of the role of FDA is a kind of moral
30 Kessler, supra note 1 2, at 171 5.
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overreaching that goes far beyond the statutory role delegated to
it by Congress.
Current Scientic Studies
FDA's ban on cosmetic implants is not supported by the general
scientic community. There is no solici scientic data showing a
causal connection between silicone and immune-system disorders|
only anecdotal evidence. And it was on the basis of this merely
anecdotal evidence that FDA decided to ban cosmetic breast im-
plants.
But, signicantly, within the last seven months, important con-
trolled studies have appeared in major journals that show no re-
lationship between silicone breast implants and an increased risk of
connective tissue and other forms of auto-immune disease. The most
signicant of these, Gabriel et al.'s Mayo Clinic Stud~ was an eight-
year retrospective cohort study of all 749 women in Olmsted County,
Minnesota, who had received a breast implant between 1964 and 1
991 31 There have also been e studies that indicate that women who
undergo breast augmentation with silicone breast implants have a
lower risk of breast cancer than the general population.32
These studies represent the best currently available scientic knowl-
edge on the medical risks associated silicone breast implants.
31 Shenne E. Gabriel et al., Risk of Connective-Tissue Diseases and
Other Disorders After Breast Implantation, 330 N. ENG. J. MED. 1967
(1994).
32 Hans Berkel et al., Breast Augmentation: A Risk Factor for Breast Can-
cer? 326 N. ENG. J. MED. 1649 (1992)
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And they do not oer support for FDA's current policy banning
cosmetic breast implants.
No Safer Alternatives
No safer alternatives to silicone gel implants are currently on
the market. Saline-lled implants (which are encased in a silicone
envelope) have elicited the same anecdotal reports and concerns as
silicone gel implants (in addition to reports of sudden deation),
and all other substances currently being tested{for example, soy
bean oil{still must undergo years of testing before their safety and
eectiveness can be determined.
Thus, a blanket long-term ban on all cosmetic breast implants in the
United States may lead desparate patients to take extreme measures.
Many will go to other countries to have the surgery performed under
considerably less safe and less controlled conditions.
Sucient Protections
There are already protections in place to discourage rash or ill-
considered decisions in regard to breast implants. After all, we are
not talking about an over-the-counter drug a patient can pick up
at her nearest pharmacy. This is a surgical procedure that must
be performed by a qualied and knowledgeable physician, that re-
quires the patient's written informed consent, and that necessitates
considerable advance planning. The patient desiring this procedure
must be willing to experience the pain and risks associated with any
surgery; in addition, because cosmetic procedures are not covered
by
15
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health insurance, the patient must be willing to bear the costs
of this expensive procedure herself. In addition, according to cur-
rent FDA regulations, all implant recipients must participate in a
patient registry, clinical trials, and postmarket surveillance. Thus,
any patient deciding to have this procedure is not likely to make it
lightly.
In conclusion, then, yes, FDA must insist on full and complete
disclosure to the patient of all possible risks early in the decision-
making process to make certain that the patient is fully informed.
But FDA should rest the ultimate decision where it belongs{with
the patient herself. It's her life{it should be her choice.
16
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